At the outset, all study participants were initially treated
with citalopram (level 1 treatment).
The main purpose of this study was to improve mood and behavior disorders in RTT patients with venlafaxine (SNRI), and compare the results
with citalopram (SSRIs) during 6 - 8 weeks, to determine which drug offered greater efficacy and fewer side effects, as well as to compare them to risperidone, and to correlate cortisol levels in saliva with stress and drug response.
Bryan Spann, D.O., Ph.D., a neurologist and clinical director of Nantz National Alzheimer Center at Houston Methodist Neurological Institute starts
with citalopram (Celexa), a selective serotonin reuptake inhibitor (SSRI) antidepressant.
It identified 14 studies with vortioxetine and 10
with citalopram, but included only 3 and 4 of these studies in the meta - analysis.
«Vortioxetine in depression: No hint of added benefit: Inadequate limitation of the study pool for the indirect comparison
with citalopram.»
Blood samples taken from people about to start treatment
with citalopram, one of the most widely used SSRIs — a class of antidepressant — showed that those who subsequently improved in response to the drug had about half the levels of miRNA - 1202 as those who failed to respond.
Not exact matches
Due to a lack of studies of direct comparisons, the company conducted an adjusted indirect comparison
with studies that tested either vortioxetine or
citalopram against placebo.
It compared moderate and severe episodes, for which the G - BA had specified an SSRI and an SSRI plus offer of psychotherapy as appropriate comparator therapy,
with the drug
citalopram without considering psychotherapy.
McMahon and colleagues analyzed DNA samples from 1953 patients diagnosed
with major depression who were being treated
with the SSRI
citalopram (Celexa).
Their study, published online today in the journal Nature, provides fresh insight into how
citalopram and paroxetine, two of the most widely prescribed selective serotonin reuptake inhibitors, or SSRIs, interact
with and inhibit serotonin transport.
Behavioral profile in comparison
with venlafaxine, reboxetine,
citalopram, and clomipramine.
Feasibility of ASL - based phMRI
with a single dose of oral
citalopram for repeated assessment of serotonin function
In another study of patients
with social phobia that compared the effects of CBT and the antidepressant
citalopram, both treatments triggered changes in the parts of the brain that help us process, and act upon, fears.
In a new study published in Pharmacopsychiatry, Crocus sativus L. versus
citalopram in the treatment of major depressive disorder
with anxious distress: a double - blind, controlled clinical trial, saffron (Crocus sativus L.) has been shown to have both antidepressant and antianxiety effects.
60 participants finished the study and they all showed significant improvement in depression and anxiety scores,
with no significant difference in effectiveness or side effects from either the saffron or
citalopram.
66 patients
with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg / day) or
citalopram (40 mg / day) for 6 weeks.
[PMID 19996755] Serotonin transporter triallelic genotype and response to
citalopram and risperidone in dementia
with behavioral symptoms.
Lundbeck, a Danish pharmaceutical company, developed and sold a blockbuster antidepressant medicine
with the active pharmaceutical ingredient («API»)
citalopram.
Those not remitting
with or intolerant of
citalopram could receive subsequent treatment steps provided in an equipose randomized design described elsewhere.17
Major depressive disorder: similar remission rates
with bupropion, sertraline, or venlafaxine following treatment switch from
citalopram
Objective To document the short - term efficacy of a selective serotonin reuptake inhibitor (
citalopram) and interpersonal psychotherapy (IPT) in reducing depressive symptoms in patients
with CAD and major depression.